|

Datopotamab Deruxtecan (Dato-DXd) Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: DS-1062a

Pipeline

Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • AstraZeneca3
  • Queen Mary University of London1

Indications

  • Cancer4
  • Breast Cancer2
  • Metastatic Castration-resistant Prostate Cancer1
  • Biliary Tract Cancer1
  • Non-small Cell Lung Cancer (NSCLC)1

Other1 trial

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Phase 2

Chandler, Arizona1 trial

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site

Phase 3

La Jolla, California1 trial

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Research Site

Phase 1/2

Los Angeles, California1 trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.